Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase

被引:6
作者
Schrover, Rudolf J.
Adena, Michael A.
De Abreu Lourenco, Richard
Prince, H. Miles
Seymour, John F.
Wonder, Michael J.
机构
[1] Novartis Pharmaceut Australia Pty Ltd, N Ryde, NSW 2113, Australia
[2] Covance Pty Ltd, Canberra, ACT, Australia
[3] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
关键词
predictive model; CML; cytogenetic response; survival; drug evaluation;
D O I
10.1080/10428190500473055
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study sets out to investigate whether the proportion of patients with chronic myeloid leukemia (CML) in the chronic phase who achieve a major cytogenetic response (MCR) can be used as the basis for estimating long-term survival through the use of modeling. Data from seven randomized controlled trials of drugs to treat patients with CML in the chronic phase were used to explore the association between MCR and survival by way of regression analysis. The estimated weighted odds ratio for the survival of those who achieved an MCR when compared with those who did not was 7 (95% CI 5-11) at 2 years and 5 (95% CI 3-8) at 4 years. Four long-term survival models were subsequently constructed. All models were found to be robust to variations in the data included. Model D was favored using the 'Ockham's razor' principle; it suggests that the median survival may be increased by 1.8 years for every 25 percentage point increase in MCR rate. The results support the use of the proportion of patients with CML in the chronic phase with an MCR to estimate overall long-term survival.
引用
收藏
页码:1069 / 1081
页数:13
相关论文
共 34 条
[1]   UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].
ALLAN, NC ;
RICHARDS, SM ;
SHEPHERD, PCA .
LANCET, 1995, 345 (8962) :1392-1397
[2]   A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia [J].
Baccarani, M ;
Rosti, G ;
de Vivo, A ;
Bonifazi, F ;
Russo, D ;
Martinelli, G ;
Testoni, N ;
Amabile, M ;
Fiacchini, M ;
Montefusco, E ;
Saglio, G ;
Tura, S .
BLOOD, 2002, 99 (05) :1527-1535
[3]  
*BIOS, 1998, UNGRAPH WIND 4 0
[4]   Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders [J].
Bonifazi, F ;
de Vivo, A ;
Rosti, G ;
Guilhot, F ;
Guilhot, J ;
Trabacchi, E ;
Hehlmann, R ;
Hochhaus, A ;
Shepherd, PCA ;
Steegmann, JL ;
Kluin-Nelemans, HC ;
Thaler, J ;
Simonsson, B ;
Louwagie, A ;
Reiffers, J ;
Mahon, FX ;
Montefusco, E ;
Alimena, G ;
Hasford, J ;
Richards, S ;
Saglio, G ;
Testoni, N ;
Martinelli, G ;
Tura, S ;
Baccarani, M .
BLOOD, 2001, 98 (10) :3074-3081
[5]  
Braga G W, 1996, Sao Paulo Med J, V114, P1083
[6]  
Cervantes F, 2003, HAEMATOLOGICA, V88, P1117
[7]   Imatinib alone and in combination for chronic myeloid leukemia [J].
Druker, BJ .
SEMINARS IN HEMATOLOGY, 2003, 40 (01) :50-58
[8]   Mechanisms of disease - The biology of chronic myeloid leukemia [J].
Faderl, S ;
Talpaz, M ;
Estrov, Z ;
O'Brien, S ;
Kurzrock, R ;
Kantarjian, HM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :164-172
[9]   Chronic myeloid leukemia: current treatment options [J].
Goldman, JM ;
Druker, BJ .
BLOOD, 2001, 98 (07) :2039-2042
[10]   Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia [J].
Guilhot, F ;
Chastang, C ;
Michallet, M ;
Guerci, A ;
Harousseau, JL ;
Maloisel, F ;
Bouabdallah, R ;
Guyotat, D ;
Cheron, N ;
Nicolini, F ;
Abgrall, JF ;
Tanzer, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) :223-229